Genital Neoplasms, Female  >>  NOV-002  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
NOV-002 / Cellectar
NCT00345540: Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer

Completed
2
15
US
NOV-002, Oxidized Glutathione, Carboplatin, Paraplatin
Cellectar Biosciences, Inc., Massachusetts General Hospital, Dana-Farber Cancer Institute
Ovarian Cancer
05/08
06/08

Download Options